Peachtree Corners, GA – RayBiotech Life, Inc., a global leader in proteomics and translational research tools, is proud to announce a new strategic collaboration with Venebio Group, LLC, a premier life sciences consultancy renowned for its expertise in regulatory strategy and drug safety analytics.

Under the newly executed Master Services Agreement (MSA), the two companies will partner to support drug and diagnostics developers by integrating RayBiotech’s proprietary proteomics platforms and biomarker discovery services with Venebio’s deep domain expertise in regulatory planning, trial design, and evidence generation.

“This partnership creates a powerful synergy between RayBiotech’s cutting-edge technologies and Venebio’s proven leadership in regulatory and clinical strategy,” said Dr. Jarad Wilson, Associate Director of Business Development at RayBiotech. “Together, we aim to streamline the development of impactful therapeutics and diagnostics, particularly in areas of high unmet medical need.”

Venebio Group, based in Virginia, brings a strong track record of supporting biopharma innovators across every stage of development—from early discovery through post-market safety assessment and reporting. Their regulatory insights and strategic guidance will complement RayBiotech’s core offerings in high-throughput protein arrays, cytokine profiling, and antibody development.

“This agreement enables us to bring more comprehensive support to our mutual clients,” added Catherine C. Vick, MS, President & CEO of Venebio Group. “RayBiotech’s capabilities in translational biomarker discovery and clinical assay development are ideal complements to our consulting practice.”

The collaboration will facilitate customized services ranging from biomarker-driven trial design to clinical assay validation, enhancing the ability of life science companies to navigate regulatory hurdles and demonstrate therapeutic value.

About RayBiotech Life, Inc.

RayBiotech is a leader in proteomics, providing cutting-edge tools and services that accelerate discovery in disease biology, biomarker validation, and therapeutic development. Its portfolio includes antibody arrays, ELISA kits, custom assay development, and central lab services for translational and clinical research.

About Venebio Group, LLC

Venebio Group is a scientific consultancy that provides strategic support for pharmaceutical, biotechnology, and medical device companies.  Their expertise spans regulatory affairs, clinical trial and observational study design, data science and epidemiology,  pharmacovigilance, and market access strategies for high-impact therapies.